Cerdulatinib hydrochloride (Synonyms:PRT062070 hydrochloride; PRT2070 hydrochloride)
目录号 : KM11310 CAS No. : 1369761-01-2 纯度 : 98%

Cerdulatinib hydrochloride (PRT062070) 是一种选择性,具有口服活性和可逆的 ATP 竞争性的 SYK 和 JAK 的双重抑制剂,抑制 SYK 和 Tyk2、JAK1、2、3 的 IC50 值分别为 32 nM、0.5 nM、12 nM、6 nM 和 8 nM。Cerdulatinib hydrochloride 可用于研究自身免疫性疾病和B细胞恶性肿瘤。

规格 价格 是否有货 数量
5mg
In-stock
10mg
In-stock
50mg
In-stock
100mg
In-stock
200mg 询价 In-stock
500mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.

体外研究

Cerdulatinib (0.03-4 μM) inhibits ERK Y204 phosphorylation with an IC50 of 0.5 μM and reduces the ability to upregulate cellsurface expression of the early activation marker CD69 with an IC50 of 0.11 μM in B cells in human whole blood.
Cerdulatinib (0.015-2 μM) inhibits FcεRI-mediated basophil degranulation with an IC50 of 0.12 μM.
Cerdulatinib (0.5-4 μM) exhibits differential potency against cytokine JAK/STAT signaling pathways.
Cerdulatinib (0-15 μM; 72 hours) results in viability effects similar to that of the combines SYK plus JAK-selective inhibition.
Cerdulatinib (1-3 μM; 48 hours) induces apoptosis in BCR-signaling competent non-Hodgkin lymphoma (NHL) cell lines.

Cell Viability Assay

Cell Line: SU-DHL4; SU-DHL6; Ramosand and Daudi cells
Concentration: 0, 1, 3 μM
Incubation Time: 48 hours
Result: Inhibits cells viability with the IC50s of 0.73-1.39 μM.

Apoptosis Analysis

Cell Line: SU-DHL4, SU-DHL6, and Ramos cells
Concentration: 0, 1.6, 5.0, 15 μM
Incubation Time: 72 hours
Result: Induced SU-DHL4, SU-DHL6, and Ramos cells apoptosis.
体内研究

Cerdulatinib (0.5-5 mg/kg; twice daily p.o. for 2 weeks) elicits dose-dependent efficacy in the rat collagen-induced arthritis (CIA) model.
Cerdulatinib ( mg/kg; twice daily p.o. for 5 days) blocks BCR-induced B-cell activation and splenomegaly in mice.

Animal Model: Female Lewis rats (7-8 weeks old; 159-187 g) are immunized
Dosage: 0, 0.5, 1.5, 3, 5 mg/kg
Administration: Oral gavage twice daily for 2 weeks
Result: Modulated inflammation in the rat CIA treatment model.
Affected anticollagen antibody formation.
Animal Model: Balb/c mice are received BCR stimulation
Dosage: 0, 1, 5, 15, 20, 30 mg/kg
Administration: Oral gavage twice daily for 5 days
Result: Suppressed upregulation of splenic B-cell surface CD80/86 and CD69 by>60%.
Inhibited mouse splenomegaly in a dose- and concentration-dependent manner.
分子式
C20H28ClN7O3S
分子量
482.00
CAS号
1369761-01-2
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 20 mg/mL (41.49 mM; ultrasonic and warming and heat to 80°C)

H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0747 mL 10.3734 mL 20.7469 mL
5 mM 0.4149 mL 2.0747 mL 4.1494 mL
10 mM 0.2075 mL 1.0373 mL 2.0747 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2 mg/mL (4.15 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (4.15 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2 mg/mL (4.15 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (4.15 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2 mg/mL (4.15 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (4.15 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

临床试验
科研文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号